Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Free Cash Flow (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Free Cash Flow data on record, last reported at -$41.1 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 32.41% year-over-year to -$41.1 million; the TTM value through Sep 2025 reached -$158.6 million, down 64.19%, while the annual FY2024 figure was -$119.8 million, 292.21% down from the prior year.
  • Free Cash Flow reached -$41.1 million in Q3 2025 per ZBIO's latest filing, up from -$41.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$15.4 million in Q4 2023 and bottomed at -$41.7 million in Q2 2025.
  • Average Free Cash Flow over 3 years is -$31.9 million, with a median of -$34.1 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 150.83% in 2024, then crashed 32.41% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$15.4 million in 2023, then crashed by 150.83% to -$38.6 million in 2024, then decreased by 6.46% to -$41.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$41.1 million in Q3 2025, -$41.7 million in Q2 2025, and -$37.1 million in Q1 2025.